Category

Litigation Update: Bayer Announces a $2B Deal to Resolve Future Roundup Cancer Claims

Posted on by Edward Lott

On Friday, February 3, 2021, Bayer AG announced that it had reached a formal agreement with plaintiffs’ class counsel to resolve future Roundup claims. As part of the agreement currently awaiting approval before presiding Judge Vince Chhabria of the U.S. District Court for the Northern District of California, Bayer has committed to paying up to … Continue reading “Litigation Update: Bayer Announces a $2B Deal to Resolve Future Roundup Cancer Claims”

Mass Tort and Class Action Outlook for 2021

Posted on by Edward Lott

As we move into 2021, it is helpful to assess the current state of mass torts and class action and think about how these matters may develop over the course of the year. Despite the impact of the COVID pandemic, some matters are picking up momentum, some long-standing cases are heading toward settlement and new … Continue reading “Mass Tort and Class Action Outlook for 2021”

Litigation Update: Elmiron MDL Sent to New Jersey

Posted on by Edward Lott

On Tuesday, December 15th the JPML sent all Elmiron cases to be tried in New Jersey by U.S. Judge Brian R. Martinotti. The judge had been handling Elmiron lawsuits and had already set up processes resembling those typically followed in MDLs. Because those efforts were already far along and with a majority of the plaintiffs … Continue reading “Litigation Update: Elmiron MDL Sent to New Jersey”

COVID-19’s Impact on The Mass Tort Landscape: What to Consider

Posted on by Edward Lott

When the courts closed in March 2020 due to COVID-19, few would have foreseen the impact on so many aspects of the mass tort landscape.  Judges, attorneys, defendants, and plaintiffs alike are all feeling the ripple effects of a system that was paralyzed for nearly half a year and only slowly, and under conditions that … Continue reading “COVID-19’s Impact on The Mass Tort Landscape: What to Consider”

FDA To Host Public Meeting on Safety Communications about Medical Devices

Posted on by Edward Lott

The FDA has announced that it will be hosting an open meeting about the agency’s safety communications on medical devices to take place on November 17, 2020 at 1:00 PM – 3:30 PM ET. The objective of the meeting is to share with the public the current practices the FDA’s has in place to communicate … Continue reading “FDA To Host Public Meeting on Safety Communications about Medical Devices”

Litigation Update: New Jersey Appeals Court Reverses 2016 Summary Judgment in Ovarian Cancer Cases

Posted on by Edward Lott

On August 5, a three judge panel from the New Jersey state appeals court reversed a 2016 summary judgment granted in favor of defendants, talc manufacturer Johnson & Johnson and talc miner Imerys Talc America in cases brought by two women who allege J&J’s talc products caused their ovarian cancer. In its opinion, the panel … Continue reading “Litigation Update: New Jersey Appeals Court Reverses 2016 Summary Judgment in Ovarian Cancer Cases”

Litigation Update: Court Rules in Monsanto Appeal

Posted on by Edward Lott

On Monday, July 20, a California appellate court upheld a jury’s finding in 2018 that Monsanto’s popular weed killer, Roundup, was responsible for causing plaintiff DeWayne Johnson’s cancer.  Appearing before a three-judge Court of Appeals panel, Monsanto, a subsidiary of Bayer AG, argued that the plaintiff had failed to prove either liability or causation; they … Continue reading “Litigation Update: Court Rules in Monsanto Appeal”

2020 Mid Year Update: Mass Tort and Class Action Litigation Outlook

Posted on by Edward Lott

While many courtrooms across the country were closed in response to the COVID-19 pandemic, there are several mass torts that continued making significant progress despite the legal hiatus. Two of these were cited in our 2020 forecast: JUUL The JUUL MDL (Northern District of California) has continued to move forward since the end of 2019. … Continue reading “2020 Mid Year Update: Mass Tort and Class Action Litigation Outlook”

Litigation Update: Elmiron Linked to Serious Eye Injuries

Posted on by Edward Lott

Elmiron [Pentosan Polysulfate Sodium (PPS)] is a drug developed in 1996 by Johnson & Johnson’s subsidiary, Janssen Pharmaceuticals to treat interstitial cystitis, bladder pain and osteoarthritis.  The drug has been linked to serious eye injuries including pigmentary and retinal maculopathy and macular degeneration.  Interstitial cystitis is a disease that causes severe bladder pain and urinary … Continue reading “Litigation Update: Elmiron Linked to Serious Eye Injuries”

How Will J&J’s Move to Discontinue Baby Powder Sales Impact Its Ongoing Talc Litigation Now?

Posted on by Edward Lott

On May 19, 2020, Johnson & Johnson announced it is discontinuing North American sales of its talc-based baby powder, a product it has defended for decades in the face of lawsuits filed by consumers who say it caused cancer. This move likely would not have happened without the public attention drawn to individuals who have … Continue reading “How Will J&J’s Move to Discontinue Baby Powder Sales Impact Its Ongoing Talc Litigation Now?”

ForLawFirmsOnly Marketing, Inc. © 1994-2021 All Rights Reserved